Annals of SBV

Register      Login

VOLUME 6 , ISSUE 2 ( July-Dec, 2017 ) > List of Articles

REVIEW ARTICLE

Overactive Bladder: Changing Paradigms in Current Guidelines and Pharmacotherapy

Sanjay Sinha

Citation Information : Sinha S. Overactive Bladder: Changing Paradigms in Current Guidelines and Pharmacotherapy. 2017; 6 (2):15-20.

DOI: 10.5005/jp-journals-10085-6204

License: CC BY-NC 4.0

Published Online: 00-12-2017

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract


PDF Share
  1. Milsom I, Altman D, Cartright R, et al. Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP) and anal incontinence (AI) In: Abrams P, Cardozo L, Wagg A, et al., editors. Incontinence - 6th International Consultation on Incontinence, ICS-ICUD, 2017:15-142.
  2. Hunter KF, Wagg A, Kerridge T, Chick H, Chambers T. Falls risk reduction and treatment of overactive bladder symptoms with antimuscarinic agents: a scoping review. Neurourol Urodyn 2011;30:490-4.
  3. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37-49.
  4. Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline. J Urol;188:2455-2463
  5. Rosa GM, Ferrero S, Nitti VW, et al. Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome. Eur Urol 2016;69:311-23.
  6. Sacco E, Bientinesi R, Tienforti D, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discov 2014;9:433-48.
  7. Andersson KE, Cardozo L, Cruz F, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Wagg A, et al., editors. Incontinence - 6th International Consultation on Incontinence, ICS-ICUD, 2017. pp. 805-957.
  8. Coelho A, Antunes-Lopes T, Gillespie J, et al. Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: An immunohistochemical study. Neurourol Urodyn 2017;36:1972-1980.
  9. Chapple CR, Yamaguchi O, Ridder A, et al. Clinical proof of concept study (Blossom) shows novel 3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol Suppl 2008;7:239.
  10. Chapple C, Wyndaele JJ, Van Kerrebroeck P, et al. Dose-ranging study of once-daily mirabegron (YM178), a novel selective 3-adrenoceptor agonist, in patients with overactive bladder (OAB). Eur Urol 2010;9:249
  11. Milsom I, Altman D, Cartright R, et al. Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolapse (POP) and anal incontinence (AI) In: Abrams P, Cardozo L, Wagg A, et al., editors. Incontinence - 6th International Consultation on Incontinence, ICS-ICUD, 2017:15-142.
  12. Hunter KF, Wagg A, Kerridge T, Chick H, Chambers T. Falls risk reduction and treatment of overactive bladder symptoms with antimuscarinic agents: a scoping review. Neurourol Urodyn 2011;30:490-4.
  13. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61:37-49.
  14. Gormley EA, Lightner DJ, Faraday M, et al. Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA/SUFU Guideline. J Urol;188:2455-2463
  15. Rosa GM, Ferrero S, Nitti VW, et al. Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome. Eur Urol 2016;69:311-23.
  16. Sacco E, Bientinesi R, Tienforti D, et al. Discovery history and clinical development of mirabegron for the treatment of overactive bladder and urinary incontinence. Expert Opin Drug Discov 2014;9:433-48.
  17. Andersson KE, Cardozo L, Cruz F, et al. Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Wagg A, et al., editors. Incontinence - 6th International Consultation on Incontinence, ICS-ICUD, 2017. pp. 805-957.
  18. Coelho A, Antunes-Lopes T, Gillespie J, et al. Beta-3 adrenergic receptor is expressed in acetylcholine-containing nerve fibers of the human urinary bladder: An immunohistochemical study. Neurourol Urodyn 2017;36:1972-1980.
  19. Chapple CR, Yamaguchi O, Ridder A, et al. Clinical proof of concept study (Blossom) shows novel 3 adrenoceptor agonist YM178 is effective and well tolerated in the treatment of symptoms of overactive bladder. Eur Urol Suppl 2008;7:239.
  20. Chapple C, Wyndaele JJ, Van Kerrebroeck P, et al. Dose-ranging study of once-daily mirabegron (YM178), a novel selective 3-adrenoceptor agonist, in patients with overactive bladder (OAB). Eur Urol 2010;9:249
  21. Nitti VW, Auerbach S, Martin N, et al. Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013;189:1388-95.
  22. Khullar V, Amarenco G, Angulo JC, et al. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol. 2013;63:283.295.
  23. Herschorn S, Barkin J, Castro-Diaz D, et al. A phase III, randomized, double-blind, parallel-group, placebo controlled, multicentre study to assess the efficacy and safety of the beta3 adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder. Urology. 2013;82:313.320.
  24. Otsuki H, Kosaka T, Nakamura K, et al. β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men. Int Urol Nephrol. 2013;45:53-60.
  25. Tubaro A, Batista JE, Nitti VW, et al. Efficacy and safety of daily mirabegron 50 mg in male patients with overactive bladder: a critical analysis of five phase III studies. Ther Adv Urol 2017;9:137-154.
  26. Wada N, Iuchi H, Kita M, et al. Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder. Low Urin Tract Symptoms 2016;8:171-6.
  27. Morin F, Blais AS, Nadeau G, et al. Dual Therapy for Refractory Overactive Bladder in Children: A Prospective Open-Label Study. J Urol 2017;197:1158-1163.
  28. Drake MJ, Nitti VW, Ginsberg DA, et al. Comparative assessment of the efficacy of onabotulinumtoxin A and oral therapies (anticholinergics and mirabegron) for overactive bladder: a systematic review and network meta-analysis. BJU Int 2017;120:611-622.
  29. Sharaf A, Hashim H. Profile of mirabegron in the treatment of overactive bladder: place in therapy. Drug Des Devel Ther 2017;11:463-467.
  30. Chapple C, Kaplan S, Mitcheson D, et al. Randomised, double-blind, active-controlled phase III study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 2013;63:296.305.
  31. Yoshida M, Nozawa Y, Kato D, et al. Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder Aged. 75 Years: Analysis of a Japanese Post-Marketing Study. Low Urin Tract Symptoms 2017. doi: 10.1111/luts.12190. (Epub ahead of print)
  32. Yeaw J, Benner JS, Walt JG, et al. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm 2009;15:728-40.
  33. Chapple CR, Nazir J, Hakimi Z, et al. Persistence and Adherence with Mirabegron versus Antimuscarinic Agents in Patients with Overactive Bladder: A Retrospective Observational Study in UK Clinical Practice. Eur Urol 2017;72:389-399.
  34. Kato D, Uno S, Van Schyndle J, et al. Persistence and adherence to overactive bladder medications in Japan: A large nationwide real-world analysis. Int J Urol 2017;24:757-764.
  35. Burkhard FC, Bosch JLHR, Cruz F, et al. European Association of Urology Guidelines on Urinary Incontinence 2017. Accessed on October 16, 2017 from https://uroweb.org/guideline/urinary-incontinence/
  36. Mirabegron for treating symptoms of overactive bladder. National Institute for Health and Care Excellence, 2013. Accessed on October 16, 2017 from https://www.nice.org.uk/guidance/ta290
  37. Abrams P, Kelleher C, Staskin D, et al. Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol 2015;67:577.588
  38. Macdiarmid S, Al-Shukri S, Barkin J, et al. Mirabegron as add-on treatment to solifenacin in patients with incontinent overactive bladder and an inadequate response to solifenacinmonotherapy. J Urol 2016;196:809.818.
  39. Gibson W, MacDiarmid S, Huang M, et al. Treating Overactive Bladder in Older Patients with a Combination of Mirabegron and Solifenacin: A Prespecified Analysis from the BESIDE Study. Eur Urol Focus 2017 Sep 12. pii: S2405-4569(17)30200-6. doi: 10.1016/j.euf.2017.08.008. (Epub ahead of print)
  40. Shin JH, Kim A, Choo MS. Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy. Investig Clin Urol 2017;58:261-266.
  41. Groen-Wijnberg M, van Dijk J, Krauwinkel W, et al. Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives. Eur J Drug Metab Pharmacokinet 2017;42:417-429.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.